Related Experiment Video

Updated: May 12, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells

Jason R Todd1, Therese M Becker, Richard F Kefford

  • 1Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW, Australia.

Pigment Cell & Melanoma Research
|April 16, 2013
PubMed

Insights

Melanoma patients with c-Kit mutations resistant to imatinib may benefit from alternative tyrosine kinase inhibitors or combined pathway inhibition. Further research into acquired resistance mechanisms is crucial for effective treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Activating c-Kit receptor tyrosine kinase mutations occur in 20-40% of specific melanoma subtypes.
  • While imatinib is effective, most patients with c-Kit mutant melanoma develop resistance.

Purpose of the Study:

  • To investigate acquired resistance mechanisms to imatinib and nilotinib in c-Kit mutant melanoma.
  • To identify potential alternative therapeutic strategies for resistant melanoma.

Main Methods:

  • Generation and analysis of imatinib- and nilotinib-resistant melanoma sublines.
  • Sequencing of c-Kit to identify secondary mutations.
  • Testing sensitivity to various tyrosine kinase inhibitors and pathway inhibitors.

Main Results:

  • Acquired secondary c-Kit mutations (A829P, T670I) confer resistance to imatinib and nilotinib.
  • The T670I mutation confers resistance to multiple inhibitors but retains sensitivity to sunitinib.
  • Concurrent inhibition of MAPK and PI3K pathways induced apoptosis in resistant melanoma cells.

Conclusions:

  • Secondary c-Kit mutations drive resistance to targeted therapies in melanoma.
  • Alternative RTK inhibitors (e.g., sunitinib) and combined pathway inhibition (MAPK/PI3K) show promise for treating resistant melanoma.
  • This study provides a rationale for personalized treatment approaches in advanced melanoma.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...